Alek has a diverse background in drug development spanning more than thirty years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US-based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney-based contract research organisation working with hundreds of clinical stage biotech companies over a twenty-one year period. Alek holds a BPharm and an MBA from the University of Sydney.

Graeme has a forty-year background in Pharma and Biotech across Europe, USA and Japan. After his pharmacology studies, he held senior R&D roles in the UK and USA in multinational companies such as Roche, GSK and Wellcome Research Laboratories. Graeme was President and CEO of Takeda Ventures, the corporate venture arm of Takeda Pharmaceuticals, a global pharmaceutical company. He is a dealmaker with extensive experience in all aspects of venture capital investing, including exits. Graeme holds a BSc and a PhD in Pharmacology.

Lorna has more than twenty years of experience in private equity and venture capital with roles at EQT, Hermes GPE, Citco, Coller Capital, Ariadne Capital, Actis and BancBoston Capital. She holds a BA in Applied Psychology and is registered with the Chartered Institute of Management Accountants (ACMA).

Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate startup entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.

Julia has a thirty-year background in Pharma and CRO, with companies such as Johnson & Johnson, Iqvia and Novotech. She also has experience in clinical nursing and research.

Katie has a strong background in venture formation, investment and the healthcare industry. She has held roles in Health Economics and Market Access and Account Management at Johnson & Johnson, and within the Life Sciences investment team at Mercia Asset Management. She also has experience in venture creation, playing a key role in the formation of Promatix Biosciences. She holds a BMedSc in Medical Science and an MPhil in Bioscience Enterprise from the University of Cambridge.

Andre has a background in big pharma and research in organisations such as GSK and the Broad Institute of MIT and Harvard. He has a history of working in investment funds, as well as early-stage life science ventures. He holds a BSc in Biochemistry and MPhil in Bioscience Enterprise from Cambridge University.

Diana provides a broad range of support to the ALSA Ventures team. She works collaboratively with individuals across all organisational levels and is responsible for handling administrative duties, facilitating internal and external communication, and increasing efficiency in business operational functions.